Mylan Wins Costs After Neurim Drops EU Patent Appeal
After initially losing a bid to invalidate an insomnia drug patent, Mylan was dubbed the winner and convinced a London judge to award costs after Neurim Pharmaceuticals abandoned its bid to...To view the full article, register now.
Already a subscriber? Click here to view full article